People who are living with HIV in Ontario have access to good health care and medications, yet they are still dying younger and at substantially higher rates than the rest of the population, according to a new study published today.
The Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) trial funded by the Medical Research Council (UK) and ANRS (France) has highlighted the benefits of new therapeutic regimens in the treatment of cryptococcal meningitis, a frequent and severe opportunistic disease in patients living with HIV. In light of these findings, reported in the March 15, 2018, issue of the New England Journal of Medicine, the WHO has changed its guidelines regarding treatment of this fungal infection.
New University at Buffalo research that investigated the language preferences of Hispanic Americans seeking HIV testing in New York found that the majority of Hispanic patients preferred to receive care in Spanish, even if they were fluent in English.
Researchers at UC Davis Health, together with colleagues at UC San Francisco and the University of North Carolina at Chapel Hill, have found a mechanism for making HIV come out of hiding and become susceptible to anti-HIV drugs. Their study is published in The Journal of Clinical Investigation.
Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to an interim analysis of study data. Additionally, the rate of HIV infection among participants in the study, which has no placebo arm for comparison, is half of what might be expected without the ring, according to mathematical modeling that has significant limitations.
Interim data from a large open-label study of the monthly dapivirine ring have found increased product use compared to a previous Phase III study. In addition, modeling data suggest that women's HIV-1 risk in the open-label study, known as DREAM, was reduced by more than half. Developed by the nonprofit International Partnership for Microbicides (IPM), the monthly ring slowly releases the antiretroviral drug dapivirine and is currently under regulatory review.
Home-based HIV testing and prompt treatment with antiretroviral therapy increases the number of patients under treatment as well as treatment success. This is the key result of a clinical trial in Lesotho carried out by the Swiss Tropical and Public Health Institute, in collaboration with SolidarMed and the Government of Lesotho. The results published today in the Journal of the American Medical Association (JAMA) lead the way for future treatment strategies against HIV/AIDS in sub-Sahara Africa.
Midway into a study in which all participants are offered use of a monthly vaginal ring containing an antiretroviral drug called dapivirine, researchers have seen women's risk of acquiring HIV reduced by more than half. Preliminary results of the HOPE open-label study of the dapivirine ring also suggest that women are using the ring more than they did in the parent ASPIRE Phase III trial, researchers from the Microbicide Trials Network are reporting.
A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. Adults and adolescents in the trial were more likely to complete the short-course regimen -- consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks -- than the standard nine-month regimen of daily isoniazid.
The STATIS trial (sponsor Inserm-ANRS) has compared two innovative strategies designed to reduce mortality in severely immunosuppressed HIV-infected adults. Coordinated by Professors François-Xavier Blanc (CHU de Nantes) and Serge Domoua (Programme PAC-CI, CHU de Treichville, Abidjan), the trial is being conducted in Cambodia, Côte d'Ivoire, Uganda, and Vietnam. The results will be presented this Monday, March 5, at the Conference on Retroviruses and Opportunistic Infections held in Boston from March 4-7, 2018.